Company: BNBX
Filing Date: 2025-12-22
Form Type: S-1/A
Source: 0001104659-25-123402
Chunk: 24

Company: BNB PLUS CORP.
Filing Date: 2025-12-22
Form: S-1/A
Chunk 24
---
 2025, the Company has sold 10,759 shares of common stock with net proceeds of $31,791, after deducting
commissions of $983.

Chief Investment Officer

On October 1, 2025,
we appointed Patrick Horsman, an affiliate of the Services Provider and Strategic Advisor, as the Chief Investment Officer of the Company.
Mr. Horsman receives monthly consulting compensation of $29,167 for serving as the Company’s Chief Investment Officer but
is not an executive officer of the Company. Mr. Horsman is also a member of the Strategic Advisor, which together with its affiliates
provides services to the Company for compensation of approximately $720,000 on an annual basis.

<div align='center'>10</div>

Significant Addition to BNB Treasury Strategy

On December 9, 2025,
the Company announced that it had opportunistically deployed approximately $3 million to acquire additional BNB tokens at an average
price of approximately $895 per token, further strengthening the Company’s yield focused BNB treasury strategy. As of December 15,
2025, the Company holds a total of approximately 18,830 BNB through direct holdings and OBNB Trust Units.

Company Information

We are a Delaware corporation,
which was initially formed in 1983 under the laws of the State of Florida as Datalink Systems, Inc. In 1998, we reincorporated in
the State of Nevada, and in 2002, we changed our name to Applied DNA Sciences, Inc. On December 17, 2008, we reincorporated
from the State of Nevada to the State of Delaware. On November 13, 2025 we changed our Company name to our current name, BNB Plus
Corp.

Our corporate headquarters
are located at the Long Island High Technology Incubator at Stony Brook University in Stony Brook, New York, where we have established
laboratories for the manufacture and development of our nucleic acid production solutions. The mailing address of our corporate headquarters
is 50 Health Sciences Drive, Stony Brook, New York 11790, and our telephone number is (631) 240-8800.

Available Information

Because we are subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we file or furnish, as applicable, annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a